Express Pharma

Three big-ticket deals contributed 69 per cent of total deal value in November 2020

The healthcare industry reported 91 VC deals worth $3.3 billion in November 2020

0 507

In November 2020, the healthcare industry reported 58 deals worth $13.5 billion as compared to the last 12-month average (November 2019 to October 2020) of 81 deals worth $14.5 billion.

CBPO Group to acquire China Biologic Products Holdings, an integrated plasma-based biopharma company for an equity value of approximately $4.7 billion;  Merck & Co to acquire all outstanding shares of VelosBio, a clinical-stage biopharmaceutical company developing novel, ROR1-directed therapeutics for $2.7 billion; Novo Nordisk A/S to acquire Emisphere Technologies (Emisphere), a drug delivery company with proprietary technologies, such as the Eligen SNAC technology, which enable oral formulations of therapeutics, for $1.8 billion are the three major deals that contributed 69 per cent of the total deal value during November 2020

Deal DateAcquirer (s)TargetDeal Value ($ m)
19-Nov-20CBPO Holdings Ltd (China)China Biologic Products Holdings Inc (China)4,760.0
5-Nov-20Merck & Co Inc (US)VelosBio Inc (US)2,750.0
6-Nov-20Novo Nordisk AS (Denmark)Emisphere Technologies Inc (US)1,800.0
12-Nov-20Sumitovant Biopharma Inc (US)Urovant Sciences Inc (US)681.0
2-Nov-20Royalty Pharma (US)Residual Royalty Interest of cystic fibrosis (CF) treatments (US)650.0

Venture capital investments value increased in November 2020

The healthcare industry reported 91 venture capital (VC) deals worth $3.3 billion in November 2020, compared to the last 12-month average (November 2019 to October 2020) of 119 deals worth $2.7 billion.

RecBio, a biotechnology company raising $227 million in series B round of financing to build a production base and conduct clinical tests of its 9-valent HPV vaccine and recombinant COVID vaccine; D3 Bio, a biotechnology company focused on developing and commercialising precision medicines, raising $200 million in series A round of financing to support the development of its portfolio in oncology and immunology; and CARsgen Therapeutics Holdings, a biotechnology company raising $186 million in series C round of financing to accelerate global clinical trials of its cell therapy product candidate are the major VC deals reported in November 2020.

Deal DateAcquirer (s)TargetDeal Value ($ m)
11-Nov-20Legend Capital Co Ltd; LYFE Capital; Sequoia Capital; Vertex Ventures; HT Capital; Co-Stone Asset Management; Yuanbio Venture Capital; Qingsong Capital; China Everbright LimitedRecBio (China)227.0
17-Nov-20Boyu Capital Consultancy Co. Ltd; Undisclosed Investor(s); Sequoia Capital China; Temasek Holdings (HK) Limited; Matrix Partners China; WuXi AppTec Corporate Venture FundD3 Bio Inc (China)200.0
2-Nov-20Lilly Asia Ventures; Shiyu Capital Group LP; Summer Capital; Loyal Valley Capital; South China Venture CapitalCARsgen Therapeutics Holdings Limited (China)186.0
26-Nov-20CCB International Capital Ltd; Matrix Partners China; Efung Capital; Tianjin Venture Capital Management Co Ltd; Chengdu Tianfu International Bio-town Investment & Development Co LTD; Sinopharma-CICC CapitalBeijing Biostar Technologies Ltd (China)135.2
23-Nov-20Falcon Edge Capital, LP; Pura Vida Investments LLC; Christian Angermayer; Apeiron Investment Group Ltd; Galaxy Investment Partners Fund LLC; Future Ventures; Catalio Capital Management LP; Undisclosed Investor(s); Peter ThielAtai Life Sciences AG (Germany)125.0

Source: GlobalData

- Advertisement -